Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Mar 15;97(6):1535–1544. doi: 10.1172/JCI118576

Presence of hypochlorite-modified proteins in human atherosclerotic lesions.

L J Hazell 1, L Arnold 1, D Flowers 1, G Waeg 1, E Malle 1, R Stocker 1
PMCID: PMC507214  PMID: 8617887

Abstract

Oxidation of LDL may contribute to atherogenesis, though the nature of the in vivo oxidant(s) remains obscure. Myeloperoxidase, the enzyme responsible for hypochlorous acid/hypochlorite (HOCl) production in vivo, is present in active form in human atherosclerotic lesions, and HOCl aggregates and transforms LDL into a high-uptake form for macrophages in vitro. Here we demonstrate HOCl-modified proteins in human lesions using an mAb raised against HOCl-modified LDL that recognizes HOCl-oxidized proteins but does not cross-react with Cu2+-, malondialdehyde-, or 4-hydroxynonenal-modified LDL. This antibody detected significantly more material in advanced atherosclerotic lesions than normal arteries, even though azide and methionine were included during sample work-up to inhibit myeloperoxidase and to scavenge HOCl. The epitope(s) recognized was predominantly cell associated and present in monocyte/macrophages, smooth muscle, and endothelial cells. The intima and cholesterol clefts stained more heavily than the center of the thickened vessels; adventitial staining was apparent in some cases. Immunostaining was also detected in a very early lesion from an accident victim, beside healthy areas that were unreactive. LDL oxidized by HOCl in vitro, but not native LDL, effectively competed with the epitopes in lesions for antibody binding. Density centrifugation of plaque homogenates and Western blot analysis showed that, in the apo B-containing lipoprotein fraction, the mAb recognized protein(s) of molecular mass greater than apo B, similar to those produced during oxidation of LDL with HOCl in vitro. Three major proteins were recognized by the anti-HOCl-modified protein antibody but not by an anti-apo B antibody in the apo B-free fraction. Together, these results demonstrate HOCl-oxidized proteins in human atherosclerotic lesions, implicating this oxidant in LDL modification in vivo.

Full Text

The Full Text of this article is available as a PDF (767.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boyd H. C., Gown A. M., Wolfbauer G., Chait A. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am J Pathol. 1989 Nov;135(5):815–825. [PMC free article] [PubMed] [Google Scholar]
  2. Daugherty A., Dunn J. L., Rateri D. L., Heinecke J. W. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest. 1994 Jul;94(1):437–444. doi: 10.1172/JCI117342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Daugherty A., Zweifel B. S., Sobel B. E., Schonfeld G. Isolation of low density lipoprotein from atherosclerotic vascular tissue of Watanabe heritable hyperlipidemic rabbits. Arteriosclerosis. 1988 Nov-Dec;8(6):768–777. doi: 10.1161/01.atv.8.6.768. [DOI] [PubMed] [Google Scholar]
  4. Frei B., Stocker R., Ames B. N. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9748–9752. doi: 10.1073/pnas.85.24.9748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gerrity R. G. The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol. 1981 May;103(2):181–190. [PMC free article] [PubMed] [Google Scholar]
  6. Haberland M. E., Fong D., Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 1988 Jul 8;241(4862):215–218. doi: 10.1126/science.2455346. [DOI] [PubMed] [Google Scholar]
  7. Hazell L. J., Stocker R. Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprotein into a high-uptake form for macrophages. Biochem J. 1993 Feb 15;290(Pt 1):165–172. doi: 10.1042/bj2900165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hazell L. J., van den Berg J. J., Stocker R. Oxidation of low-density lipoprotein by hypochlorite causes aggregation that is mediated by modification of lysine residues rather than lipid oxidation. Biochem J. 1994 Aug 15;302(Pt 1):297–304. doi: 10.1042/bj3020297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Heinecke J. W., Li W., Mueller D. M., Bohrer A., Turk J. Cholesterol chlorohydrin synthesis by the myeloperoxidase-hydrogen peroxide-chloride system: potential markers for lipoproteins oxidatively damaged by phagocytes. Biochemistry. 1994 Aug 23;33(33):10127–10136. doi: 10.1021/bi00199a041. [DOI] [PubMed] [Google Scholar]
  10. Hoff H. F., O'Neil J. Lesion-derived low density lipoprotein and oxidized low density lipoprotein share a lability for aggregation, leading to enhanced macrophage degradation. Arterioscler Thromb. 1991 Sep-Oct;11(5):1209–1222. doi: 10.1161/01.atv.11.5.1209. [DOI] [PubMed] [Google Scholar]
  11. Hu M. L., Louie S., Cross C. E., Motchnik P., Halliwell B. Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med. 1993 Feb;121(2):257–262. [PubMed] [Google Scholar]
  12. Jürgens G., Chen Q., Esterbauer H., Mair S., Ledinski G., Dinges H. P. Immunostaining of human autopsy aortas with antibodies to modified apolipoprotein B and apoprotein(a). Arterioscler Thromb. 1993 Nov;13(11):1689–1699. doi: 10.1161/01.atv.13.11.1689. [DOI] [PubMed] [Google Scholar]
  13. Kikugawa K., Kato T., Hayasaka A. Formation of dityrosine and other fluorescent amino acids by reaction of amino acids with lipid hydroperoxides. Lipids. 1991 Nov;26(11):922–929. doi: 10.1007/BF02535978. [DOI] [PubMed] [Google Scholar]
  14. Malle E., Hazell L., Stocker R., Sattler W., Esterbauer H., Waeg G. Immunologic detection and measurement of hypochlorite-modified LDL with specific monoclonal antibodies. Arterioscler Thromb Vasc Biol. 1995 Jul;15(7):982–989. doi: 10.1161/01.atv.15.7.982. [DOI] [PubMed] [Google Scholar]
  15. Morton R. E., Evans T. A. Modification of the bicinchoninic acid protein assay to eliminate lipid interference in determining lipoprotein protein content. Anal Biochem. 1992 Aug 1;204(2):332–334. doi: 10.1016/0003-2697(92)90248-6. [DOI] [PubMed] [Google Scholar]
  16. O'Connell A. M., Gieseg S. P., Stanley K. K. Hypochlorite oxidation causes cross-linking of Lp(a). Biochim Biophys Acta. 1994 Jan 11;1225(2):180–186. doi: 10.1016/0925-4439(94)90076-0. [DOI] [PubMed] [Google Scholar]
  17. Palinski W., Rosenfeld M. E., Ylä-Herttuala S., Gurtner G. C., Socher S. S., Butler S. W., Parthasarathy S., Carew T. E., Steinberg D., Witztum J. L. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A. 1989 Feb;86(4):1372–1376. doi: 10.1073/pnas.86.4.1372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Palinski W., Ylä-Herttuala S., Rosenfeld M. E., Butler S. W., Socher S. A., Parthasarathy S., Curtiss L. K., Witztum J. L. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis. 1990 May-Jun;10(3):325–335. doi: 10.1161/01.atv.10.3.325. [DOI] [PubMed] [Google Scholar]
  19. Rosenfeld M. E., Khoo J. C., Miller E., Parthasarathy S., Palinski W., Witztum J. L. Macrophage-derived foam cells freshly isolated from rabbit atherosclerotic lesions degrade modified lipoproteins, promote oxidation of low-density lipoproteins, and contain oxidation-specific lipid-protein adducts. J Clin Invest. 1991 Jan;87(1):90–99. doi: 10.1172/JCI115006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rosenfeld M. E., Palinski W., Ylä-Herttuala S., Butler S., Witztum J. L. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 1990 May-Jun;10(3):336–349. doi: 10.1161/01.atv.10.3.336. [DOI] [PubMed] [Google Scholar]
  21. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993 Apr 29;362(6423):801–809. doi: 10.1038/362801a0. [DOI] [PubMed] [Google Scholar]
  22. Salmon S., Maziere C., Theron L., Beucler I., Ayrault-Jarrier M., Goldstein S., Polonovski J. Immunological detection of low-density lipoproteins modified by malondialdehyde in vitro or in vivo. Biochim Biophys Acta. 1987 Aug 15;920(3):215–220. doi: 10.1016/0005-2760(87)90097-x. [DOI] [PubMed] [Google Scholar]
  23. Salonen J. T., Ylä-Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., Nyyssönen K., Palinski W., Witztum J. L. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992 Apr 11;339(8798):883–887. doi: 10.1016/0140-6736(92)90926-t. [DOI] [PubMed] [Google Scholar]
  24. Sattler W., Mohr D., Stocker R. Rapid isolation of lipoproteins and assessment of their peroxidation by high-performance liquid chromatography postcolumn chemiluminescence. Methods Enzymol. 1994;233:469–489. doi: 10.1016/s0076-6879(94)33053-0. [DOI] [PubMed] [Google Scholar]
  25. Savenkova M. L., Mueller D. M., Heinecke J. W. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. J Biol Chem. 1994 Aug 12;269(32):20394–20400. [PubMed] [Google Scholar]
  26. Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., Gartner F. H., Provenzano M. D., Fujimoto E. K., Goeke N. M., Olson B. J., Klenk D. C. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985 Oct;150(1):76–85. doi: 10.1016/0003-2697(85)90442-7. [DOI] [PubMed] [Google Scholar]
  27. Stary H. C., Chandler A. B., Glagov S., Guyton J. R., Insull W., Jr, Rosenfeld M. E., Schaffer S. A., Schwartz C. J., Wagner W. D., Wissler R. W. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb. 1994 May;14(5):840–856. doi: 10.1161/01.atv.14.5.840. [DOI] [PubMed] [Google Scholar]
  28. Steinberg D., Parthasarathy S., Carew T. E., Khoo J. C., Witztum J. L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989 Apr 6;320(14):915–924. doi: 10.1056/NEJM198904063201407. [DOI] [PubMed] [Google Scholar]
  29. Steinbrecher U. P., Zhang H. F., Lougheed M. Role of oxidatively modified LDL in atherosclerosis. Free Radic Biol Med. 1990;9(2):155–168. doi: 10.1016/0891-5849(90)90119-4. [DOI] [PubMed] [Google Scholar]
  30. Stroncek D. F., Vercellotti G. M., Huh P. W., Jacob H. S. Neutrophil oxidants inactivate alpha-1-protease inhibitor and promote PMN-mediated detachment of cultured endothelium. Protection by free methionine. Arteriosclerosis. 1986 May-Jun;6(3):332–340. doi: 10.1161/01.atv.6.3.332. [DOI] [PubMed] [Google Scholar]
  31. Vissers M. C., Winterbourn C. C. Oxidative damage to fibronectin. I. The effects of the neutrophil myeloperoxidase system and HOCl. Arch Biochem Biophys. 1991 Feb 15;285(1):53–59. doi: 10.1016/0003-9861(91)90327-f. [DOI] [PubMed] [Google Scholar]
  32. Winterbourn C. C., van den Berg J. J., Roitman E., Kuypers F. A. Chlorohydrin formation from unsaturated fatty acids reacted with hypochlorous acid. Arch Biochem Biophys. 1992 Aug 1;296(2):547–555. doi: 10.1016/0003-9861(92)90609-z. [DOI] [PubMed] [Google Scholar]
  33. Ylä-Herttuala S., Palinski W., Butler S. W., Picard S., Steinberg D., Witztum J. L. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb. 1994 Jan;14(1):32–40. doi: 10.1161/01.atv.14.1.32. [DOI] [PubMed] [Google Scholar]
  34. Ylä-Herttuala S., Palinski W., Rosenfeld M. E., Parthasarathy S., Carew T. E., Butler S., Witztum J. L., Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989 Oct;84(4):1086–1095. doi: 10.1172/JCI114271. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES